Clinical Research Directory
Browse clinical research sites, groups, and studies.
Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
Sponsor: Rennes University Hospital
Summary
ATTRv amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms). Patisiran and vutrisiran have shown protective effects on the progression of neurological damage. The effects of Patisiran or vutrisiran on the heart remain incompletely understood. The aim of this study is to better understand the morphological and functional cardiac consequences in ATTRv patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran or vutrisiran
Official title: MyocardON-TTR - Myocardial Effects in Patients With Hereditary Transthyretin-mediated Amyloidosis With Polyneuropathy Treated With Patisiran or Vutrisiran
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2024-04-12
Completion Date
2027-12
Last Updated
2026-01-05
Healthy Volunteers
No
Interventions
Six minutes walk test
Six minutes walk test just before first intake of treatment and after 1 and 2 years
Kansas City questionnaire
Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
COMPASS31 self questionnaire
Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
Locations (5)
CHU Bordeaux Haut-Levêque
Bordeaux, France
APHP Henri Mondor
Créteil, France
CHU Grenoble Alpes
Grenoble, France
CHU Nancy Institut Louis Mathieu
Nancy, France
CHU Rangueil Toulouse
Toulouse, France